Risk of immune-related pneumonitis for PD1/PD-L1 inhibitors: Systematic review and network meta-analysis.

ABSTRACT:

Background

Immune-related pneumonitis is a clinically relevant and potentially life-threatening adverse event. We performed a systematic review and network meta-analysis to compare the risk of immune-related pneumonitis among different PD1/PD-L1 inhibitor-related therapeutic regimens.

Methods

Randomized controlled trials with PD1/PD-L1 inhibitors were identified through comprehensive searches of multiple databases. Both published and unpublished data were extracted. Bayesian NMA was performed using random-effects models. All-grade (Grade 1-5) and high-grade (Grade 3-5) immune-related pneumonitis were estimated using odds ratios (ORs).

Results

A total of 25 studies involving 16 005 patients were included. Compared with chemotherapy, the ORs of immune-related all-grade

SUBMITTER: Huang Y 

PROVIDER: S-EPMC6536966 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature